 |
- Condition: HIV-1 Infection
Interventions: Drug: Pitavastatin; Drug: Placebos
Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Aging (NIA)
Recruiting - verified May 2017 - Condition: HIV-1
Interventions: Drug: DRV/COBI FDC placebo tablet; Drug: D/C/F/TAF FDC placebo tablets
Sponsor: Janssen Research & Development, LLC
Recruiting - verified May 2017 - Condition: HIV-1 Infection
Intervention: Drug: Antiretroviral treatment pause
Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2017 - Condition: Healthy
Interventions: Biological: Ad26.Mos4.HIV; Biological: Clade C gp140 plus adjuvant; Biological: Clade C gp140/Mosaic gp140 plus adjuvant; Other: Placebo
Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting - verified May 2017 - Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine; Biological: Bivalent Subtype C gp120/MF59 vaccine; Biological: Bivalent Subtype C gp120/AS01B vaccine; Biological: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2017 - Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine; Biological: AIDSVAX B/E vaccine; Biological: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2017 - Condition: Healthy
Interventions: Biological: Ad26.Mos.HIV; Biological: Ad26.Mos4.HIV; Biological: Clade C gp140; Drug: Placebo
Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting - verified May 2017 - Condition: HIV Infections
Intervention: Drug: Maraviroc
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2017 - Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets; Drug: TDF/FTC tablets; Drug: TDF/FTC placebo tablets; Drug: CAB placebo tablets; Drug: CAB LA; Drug: Placebo for CAB LA
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare; Gilead Sciences
Recruiting - verified June 2017 - Condition: HIV Infections
Interventions: Biological: VRC01; Biological: Placebo for VRC01
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2017 - Condition: HIV
Interventions: Drug: ibalizumab; Drug: Optimized Background Regimen
Sponsors: TaiMed Biologics Inc.; Westat
Recruiting - verified April 2017 - Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC); Drug: Placebo for dolutegravir (DTG); Drug: Dolutegravir (DTG); Drug: Maraviroc (MVC)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2017 - Condition: HIV Infections
Intervention: Drug: Ruxolitinib
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2017 - Conditions: HIV Infections; Cardiovascular Diseases
Interventions: Drug: Pitavastatin; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute (NHLBI); Kowa Pharmaceuticals America, Inc.
Recruiting - verified June 2017 - Condition: HIV-1
Interventions: Drug: F/TAF; Drug: FTC/TDF; Drug: 3rd ARV agent
Sponsor: Gilead Sciences
Recruiting - verified June 2017 - Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT); Drug: Dasabuvir (DSV); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2017 - Condition: HIV/AIDS
Intervention:
Sponsors: Harvard School of Public Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases (NIAID); NIH Office of AIDS Research (OAR); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Deafness and Other Communication Disorders (NIDCD); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); Tulane University School of Medicine
Recruiting - verified January 2017 - Conditions: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Interventions: Drug: ATV; Drug: DRV; Drug: Cobicistat; Drug: BR
Sponsor: Gilead Sciences
Recruiting - verified May 2017 - Condition: HIV Infections
Interventions: Drug: Romidepsin; Drug: Placebo for RMD: 0.9% sodium chloride for injection
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2017 - Conditions: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
Intervention: Drug: E/C/F/TAF
Sponsor: Gilead Sciences
Recruiting - verified June 2017 - Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2017 - Condition: HIV Infections
Intervention: Drug: Raltegravir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2017 - Condition: Antiretroviral Toxicity
Intervention:
Sponsors: Harvard School of Public Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Mental Health (NIMH); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Neurological Disorders and Stroke (NINDS); Tulane University School of Medicine; National Institute of Dental and Craniofacial Research (NIDCR); NIH Office of AIDS Research (OAR)
Recruiting - verified January 2017 - Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) film-coated tablets; Drug: DTG granules for suspension; Drug: DTG dispersible tablets
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2017 - Condition: Human Immuno Deficiency (HIV) Infection
Interventions: Drug: Rilpivirine; Drug: Zidovudine; Drug: Abacavir; Drug: Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Emtricitabine
Sponsor: Janssen Sciences Ireland UC
Recruiting - verified June 2017 - Condition: HIV Infections
Interventions: Drug: atazanavir/cobicistat; Drug: darunavir/ritonavir; Drug: darunavir/cobicistat; Drug: etravirine; Drug: elvitegravir/cobicistat; Drug: dolutegravir; Drug: tenofovir alafenamide fumarate (TAF); Drug: TAF/cobicistat; Drug: TAF/ritonavir; Drug: efavirenz; Drug: lopinavir/ritonavir; Drug: nevirapine; Drug: rifampicin; Drug: ethambutol; Drug: isoniazid; Drug: pyrazinamide; Drug: rifampicin; Drug: kanamycin; Drug: amikacin; Drug: capreomycin; Drug: moxifloxacin; Drug: levofloxacin; Drug: ofloxacin; Drug: ethionamide/prothionamide; Drug: terizidone/cycloserine; Drug: para-aminosalicylic acid (PAS); Drug: high dose isoniazid (INH); Drug: bedaquiline; Drug: clofazamine; Drug: delamanid; Drug: linezolid; Drug: pretomanid; Drug: atazanavir/ritonavir/tenofovir; Drug: ethinyl estradiol oral contraceptive; Drug: etonogestrel implant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2017 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2017
Clinical Trial Locations